Sivick et al. reported that higher doses of the STING agonist ADU S100 led to faster tumour ablation, but lower doses induced most tumour-specific T cells and an immunologic memory with successful rechallenge abrogation [45]. This evidence concerns the gene STING1 and neoplasm.